Crinetics Pharmaceuticals Croissance future

Future contrôle des critères 2/6

Crinetics Pharmaceuticals devrait augmenter ses bénéfices et son chiffre d'affaires de 9% et de 67.7% par an respectivement. Le BPA devrait croître de de 12.8% par an. Le rendement des capitaux propres devrait être -40.3% dans 3 ans.

Informations clés

9.0%

Taux de croissance des bénéfices

12.8%

Taux de croissance du BPA

Biotechs croissance des bénéfices	28.5%
Taux de croissance des recettes	67.7%
Rendement futur des capitaux propres	-40.3%
Couverture par les analystes	Good
Dernière mise à jour	22 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

We're Hopeful That Crinetics Pharmaceuticals (NASDAQ:CRNX) Will Use Its Cash Wisely

Oct 02

Crinetics Pharmaceuticals: Stop, Look, And Listen Before Buying This High-Priced Clinical Stage Biotech

Aug 12

Most Shareholders Will Probably Agree With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) CEO Compensation

Jun 01

Crinetics: Earlier Data Release For CAH Treatment Bodes Well For Upcoming Conference Data

May 23

Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade)

Feb 29

Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Nov 28

Is Crinetics Pharmaceuticals (NASDAQ:CRNX) In A Good Position To Invest In Growth?

Aug 08

Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Dec 31

Here's Why We're Not Too Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Situation

Sep 14

Crinetics Pharmaceuticals GAAP EPS of -$0.81 misses by $0.15, revenue of $0.44M misses by $0.28M

Aug 12

We're Not Very Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Rate

Jun 15

Crinetics: Late-Stage Acromegaly Disease Studies Will Be Major Inflection Point

Jun 13

Prévisions de croissance des bénéfices et des revenus

NasdaqGS:CRNX - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	50	-435	-451	N/A	9
12/31/2025	11	-354	-316	-237	12
12/31/2024	2	-296	-260	-220	12
9/30/2024	1	-278	-204	-200	N/A
6/30/2024	1	-259	-185	-178	N/A
3/31/2024	2	-235	-184	-178	N/A
12/31/2023	4	-215	-171	-166	N/A
9/30/2023	5	-199	-167	-163	N/A
6/30/2023	5	-184	-161	-160	N/A
3/31/2023	4	-175	-144	-142	N/A
12/31/2022	5	-164	-117	-115	N/A
9/30/2022	5	-150	-104	-103	N/A
6/30/2022	5	-136	-91	-90	N/A
3/31/2022	4	-119	-82	-82	N/A
12/31/2021	1	-108	-89	-89	N/A
9/30/2021	N/A	-98	-82	-82	N/A
6/30/2021	N/A	-89	-74	-74	N/A
3/31/2021	N/A	-79	-70	-70	N/A
12/31/2020	0	-74	-62	-62	N/A
9/30/2020	0	-67	-60	-60	N/A
6/30/2020	1	-63	-55	-55	N/A
3/31/2020	1	-59	-52	-52	N/A
12/31/2019	1	-50	-47	-46	N/A
9/30/2019	2	-44	-40	-39	N/A
6/30/2019	2	-38	-32	-31	N/A
3/31/2019	2	-31	-24	-23	N/A
12/31/2018	2	-27	-21	-19	N/A
9/30/2018	2	-21	-17	-16	N/A
6/30/2018	2	-16	N/A	-13	N/A
3/31/2018	2	-12	N/A	-11	N/A
12/31/2017	2	-9	N/A	-9	N/A
12/31/2016	1	-6	N/A	-5	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: CRNX devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: CRNX devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: CRNX devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de CRNX ( 67.7% par an) devrait croître plus rapidement que le marché US ( 8.9% par an).

Croissance élevée des revenus: Le chiffre d'affaires de CRNX ( 67.7% par an) devrait croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: CRNX devrait être non rentable dans 3 ans.

Crinetics Pharmaceuticals Croissance future

Future contrôle des critères 2/6

Informations clés

Mises à jour récentes de la croissance future

Consensus revenue estimates fall by 20%

Price target increased by 7.8% to US$66.43

Price target increased by 8.2% to US$61.50

Price target increased by 10% to US$59.79

Price target increased by 7.8% to US$57.23

Price target increased by 9.1% to US$54.46

Recent updates

Consensus revenue estimates fall by 20%

Third quarter 2024 earnings released: US$0.96 loss per share (vs US$1.01 loss in 3Q 2023)

Crinetics Pharmaceuticals, Inc. to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at the North American Neuroendocrine Tumor Society Annual Meeting

Crinetics Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Crinetics Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $400 million.

We're Hopeful That Crinetics Pharmaceuticals (NASDAQ:CRNX) Will Use Its Cash Wisely

Chief Financial Officer notifies of intention to sell stock

Crinetics Pharmaceuticals, Inc. Submits New Drug Application for Paltusotine for the Treatment of Acromegaly

Crinetics Pharmaceuticals: Stop, Look, And Listen Before Buying This High-Priced Clinical Stage Biotech

Crinetics Pharmaceuticals, Inc. Announces Marc Wilson Will Be Transitioning from His Role as Chief Financial Officer

Chief Financial Officer notifies of intention to sell stock

Crinetics Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Chief Operating Officer notifies of intention to sell stock

Crinetics Pharmaceuticals, Inc.(NasdaqGS:CRNX) dropped from Russell 2500 Value Index

Chief Commercial Officer notifies of intention to sell stock

Crinetics Pharmaceuticals, Inc. Presents New Data At ENDO 2024 That Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly

Price target increased by 7.8% to US$66.43

Most Shareholders Will Probably Agree With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) CEO Compensation

Crinetics Pharmaceuticals, Inc. Appoints Robert M. Cuddihy as Senior Vice President of Medical Affairs

Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts

Crinetics: Earlier Data Release For CAH Treatment Bodes Well For Upcoming Conference Data

Price target increased by 8.2% to US$61.50

Full year 2023 earnings released: US$3.69 loss per share (vs US$3.15 loss in FY 2022)

Founder notifies of intention to sell stock

Price target increased by 10% to US$59.79

Crinetics Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 09, 2024

Crinetics Pharmaceuticals, Inc., Annual General Meeting, Jun 07, 2024

Chief Development Officer notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

Price target increased by 7.8% to US$57.23

Crinetics Pharmaceuticals, Inc. Announces Positive Topline Results from PATHFNDR-2, Second of Two Phase 3 Studies Evaluating Efficacy and Safety of Oral, Once-Daily Investigational Paltusotine for Treatment of Acromegaly

Price target increased by 9.1% to US$54.46

Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome

Consensus revenue estimates decrease by 88%, EPS upgraded

Consensus revenue estimates decrease by 89%, EPS upgraded

Chief Medical Officer notifies of intention to sell stock

Full year 2023 earnings: EPS and revenues miss analyst expectations

Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade)

Crinetics Pharmaceuticals, Inc. announced that it expects to receive $350.000028 million in funding from a group of investors

Crinetics Pharmaceuticals, Inc. announced that it expects to receive $350.000028 million in funding from a group of investors

Crinetics Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Chief Medical Officer notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

Crinetics Pharmaceuticals, Inc. Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome

Chief Medical Officer notifies of intention to sell stock

Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Chief Financial Officer notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

New minor risk - Shareholder dilution

Crinetics' Once-Daily Oral Paltusotine Achieves the Primary and All Secondary Endpoints in the Phase 3 Pathfr-1 Study Evaluating Treatment of Patients with Acromegaly

Price target increased by 8.2% to US$46.78

Consensus revenue estimates fall by 18%

Price target decreased by 7.4% to US$43.63

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Is Crinetics Pharmaceuticals (NASDAQ:CRNX) In A Good Position To Invest In Growth?

Founder recently sold US$1.0m worth of stock

Founder notifies of intention to sell stock

Founder recently sold US$1.0m worth of stock

Crinetics Pharmaceuticals, Inc. Presents Efficacy, Safety and Patient-Reported Outcome Data At ENDO 2023

Founder notifies of intention to sell stock

Consensus revenue estimates increase by 154%

Chief Development Officer notifies of intention to sell stock

Chief Development Officer recently sold US$133k worth of stock

Consensus EPS estimates fall by 13%

Consensus EPS estimates fall by 12%

Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans